StreetInsider.com News Articles

Form 8-K Faeth Therapeutics, Inc. For: Sep 11

Thu, 17 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260917/27076030.html

Faeth Therapeutics adds cancer biologist Karen Vousden to its board

Thu, 17 Sep 2026 16:00:14 -0400

Faeth Therapeutics, Inc. (Nasdaq: FTH) announced the appointment of Karen Vousden, Ph.D., to its board of directors, effective September 11, 2026, according to a company press release.

Dr. Vousden is a scientific co-founder of Faeth and has served as a Principal Group Leader at The Francis Crick Institute in London since 2017. She previously served as Chief Scientist of Cancer Research UK from 2016 to 2022 and as Director of the Beatson Institute for Cancer Research from 2002 to 2016. She has also served on the board of directors of Bristol Myers Squibb Company (NYSE: BMY) since 2018.

Dr. Vousden's research has

Faeth Therapeutics adds cancer biologist Karen Vousden to its board

Thu, 17 Sep 2026 16:00:14 -0400

Faeth Therapeutics, Inc. (Nasdaq: FTH) announced the appointment of Karen Vousden, Ph.D., to its board of directors, effective September 11, 2026, according to a company press release.

Dr. Vousden's research has

Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors

Thu, 17 Sep 2026 16:00:00 -0400

Renowned cancer biologist and Faeth scientific co-founder joins the Board as the Company approaches topline Phase 2 data for PIKTOR in endometrial cancer

AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways, today announced that Karen Vousden, Ph.D., has been appointed to its Board of Directors, effective September 11, 2026.

“Karen helped shape the scientific thesis this company was built on, and she has been a trusted advisor to Faeth since its founding,” said Anand Parikh, Chairman, President and Chief

Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors

Thu, 17 Sep 2026 16:00:00 -0400

Renowned cancer biologist and Faeth scientific co-founder joins the Board as the Company approaches topline Phase 2 data for PIKTOR in endometrial cancer

“Karen helped shape the scientific thesis this company was built on, and she has been a trusted advisor to Faeth since its founding,” said Anand Parikh, Chairman, President and Chief

Form 4 Faeth Therapeutics, Inc. For: Sep 11 Filed by: Vousden Karen H

Tue, 15 Sep 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260915/27065617.html

Form 4 Faeth Therapeutics, Inc. For: Sep 11 Filed by: Vousden Karen H

Tue, 15 Sep 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260915/27065617.html

Form 3 Faeth Therapeutics, Inc. For: Sep 11 Filed by: Vousden Karen H

Tue, 15 Sep 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260915/27065603.html

Form 3 Faeth Therapeutics, Inc. For: Sep 11 Filed by: Vousden Karen H

Tue, 15 Sep 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260915/27065603.html

Guggenheim Starts Faeth Therapeutics (FTH) at Buy, PT $70

Tue, 15 Sep 2026 16:14:18 -0400

Guggenheim analyst Brad Canino initiates coverage on Faeth Therapeutics (NASDAQ: FTH) with a Buy rating and a price target of $70.00.

For an analyst ratings summary and ratings history on Faeth Therapeutics click here. For more ratings news on Faeth Therapeutics click here.

Shares of Faeth Therapeutics closed at $39.09 yesterday.

Guggenheim Starts Faeth Therapeutics (FTH) at Buy, PT $70

Tue, 15 Sep 2026 16:14:18 -0400

Guggenheim analyst Brad Canino initiates coverage on Faeth Therapeutics (NASDAQ: FTH) with a Buy rating and a price target of $70.00.

For an analyst ratings summary and ratings history on Faeth Therapeutics click here. For more ratings news on Faeth Therapeutics click here.

Shares of Faeth Therapeutics closed at $39.09 yesterday.

Lucid Capital Markets Starts Faeth Therapeutics (FTH) at Buy

Mon, 14 Sep 2026 06:35:51 -0400

Lucid Capital Markets analyst Dev Prasad initiates coverage on Faeth Therapeutics (NASDAQ: FTH) with a Buy rating and a price target of $59.00.

The analyst comments "We assume coverage of Faeth Therapeutics with a Buy rating and a $59 price target. Our investment thesis centers on PIKTOR, an oral multi-node PI3K/AKT/mTOR (PAM) regimen that combines selective PI3Kα inhibition with mTORC1/2 blockade to achieve deeper pathway suppression while potentially improving the therapeutic window versus single-node and pan-PI3K approaches. The key near-term catalyst is YE26 topline from the ~40-patient PIK-201 Phase 2 in 2L+ PAM-altered endometrioid endometrial cancer, where prior Phase 1b data

Lucid Capital Markets Starts Faeth Therapeutics (FTH) at Buy

Mon, 14 Sep 2026 06:35:51 -0400

Lucid Capital Markets analyst Dev Prasad initiates coverage on Faeth Therapeutics (NASDAQ: FTH) with a Buy rating and a price target of $59.00.

TD Cowen Starts Faeth Therapeutics (FTH) at Buy

Wed, 09 Sep 2026 07:26:57 -0400

(Updated - September 9, 2026 7:26 AM EDT)

TD Cowen initiates coverage on Faeth Therapeutics (NASDAQ: FTH) with a Buy rating.

The analyst comments "Multi-node PAM inhibition is validated and can result in improved outcomes in breast cancer and likely beyond. PIKTOR's oral administration and differentiated PK should achieve strong adoption through a favorable, practical balance of efficacy through exposure, tolerability, and convenience. PhII endometrial data by YE should validate its profile and support a $2B+ opportunity across indications."

For an analyst ratings summary and ratings history on Faeth Therapeutics click here. For more ratings news on Faeth Therapeutics click here.

TD Cowen Starts Faeth Therapeutics (FTH) at Buy

Wed, 09 Sep 2026 07:26:57 -0400

(Updated - September 9, 2026 7:26 AM EDT)

TD Cowen initiates coverage on Faeth Therapeutics (NASDAQ: FTH) with a Buy rating.

For an analyst ratings summary and ratings history on Faeth Therapeutics click here. For more ratings news on Faeth Therapeutics click here.

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 28 Aug 2026 07:30:00 -0400

AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 94,000 shares of the Company’s common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective August 25, 2026, pursuant to the Company’s 2026 Inducement Plan as a material inducement to the individuals entering employment with Faeth in accordance with Nasdaq Listing Rule 5635(c)(4).

The Option Awards have an exercise price of $34.52 per share, equal to the closing price of the Company’s

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 28 Aug 2026 07:30:00 -0400

The Option Awards have an exercise price of $34.52 per share, equal to the closing price of the Company’s

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 28 Aug 2026 07:30:00 -0400

The Option Awards have an exercise price of $34.52 per share, equal to the closing price of the Company’s

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 28 Aug 2026 07:30:00 -0400

The Option Awards have an exercise price of $34.52 per share, equal to the closing price of the Company’s

Needham Starts Faeth Therapeutics (FTH) at Buy

Fri, 21 Aug 2026 07:08:43 -0400

(Updated - August 21, 2026 7:08 AM EDT)

Needham analyst Gil Blum initiates coverage on Faeth Therapeutics (NASDAQ: FTH) with a Buy rating and a price target of $56.00.

The analyst comments "Targeting of the PI3K/AKT/mTOR signaling pathway in cancer has remained a challenge, with pharma focused on single node inhibitors. Recently approved multi-node inhibitor Revtorpyk (CELC, Buy) has demonstrated clinical benefit in both mutant and WT PI3K patients, providing a clear POC. While we expect Revtorpyk's launch to help educate stakeholders on multi-node inhibition, its IV administration may limit expansion in earlier lines, especially in advanced mBC, where SOC is shifting

Needham Starts Faeth Therapeutics (FTH) at Buy

Fri, 21 Aug 2026 07:08:43 -0400

(Updated - August 21, 2026 7:08 AM EDT)

Needham analyst Gil Blum initiates coverage on Faeth Therapeutics (NASDAQ: FTH) with a Buy rating and a price target of $56.00.

FDA grants fast track status to Faeth's PIKTOR combo for endometrial cancer

Mon, 17 Aug 2026 07:31:15 -0400

Faeth Therapeutics (Nasdaq: FTH) announced that the U.S. Food and Drug Administration has granted Fast Track designation to its investigational combination therapy PIKTOR — comprising sapanisertib and serabelisib — when used with paclitaxel for the treatment of advanced or recurrent endometrial cancer.

The designation applies specifically to patients whose tumors harbor a PI3K/AKT/mTOR pathway alteration and who have previously received platinum-based chemotherapy and an immune checkpoint inhibitor.

PIKTOR is an all-oral combination designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway. According to published literature cited by the company, this pathway is dysregulated in up to 50% of all solid tumors.

The company

FDA grants fast track status to Faeth's PIKTOR combo for endometrial cancer

Mon, 17 Aug 2026 07:31:15 -0400

The company

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer

Mon, 17 Aug 2026 07:30:00 -0400

— Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR pathway alteration

— Faeth expects topline data from its ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201) by year-end 2026

AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of sapanisertib

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer

Mon, 17 Aug 2026 07:30:00 -0400

— Faeth expects topline data from its ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201) by year-end 2026